Drug disposition and clinical practice in neonates: Cross talk between developmental physiology and pharmacology

International Journal of Pharmaceutics

Volumn 452, Issue 1-2, 2013, Pages 8-13

  Smits, Anne ^a   Annaert, Pieter ^b   Allegaert, Karel ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b DEPARTMENT OF PHARMACEUTICAL AND PHARMACOLOGICAL SCIENCES   (Belgium)

Author keywords

Covariates; Developmental pharmacology; Infant; Maturation; Newborn; Variability

Indexed keywords

AMIKACIN; CEFAZOLIN; CEFTRIAXONE; IBUPROFEN; INDOMETACIN; METHOTREXATE; MICAFUNGIN; PARACETAMOL; PROPOFOL; TRAMADOL;

ARTICLE; BLOOD FLOW; CLINICAL PHARMACOLOGY; CLINICAL PRACTICE; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIURESIS; DRUG CLEARANCE; DRUG DISPOSITION; DRUG ELIMINATION; DRUG EXCRETION; DRUG METABOLISM; DRUG TRANSFORMATION; GENETIC POLYMORPHISM; GESTATIONAL AGE; GLOMERULUS FILTRATION RATE; GLUCURONIDATION; GROWTH RETARDATION; HEART OUTPUT; HUMAN; IN VIVO STUDY; INFANCY; KIDNEY PERFUSION; KIDNEY TUBULE FUNCTION; LOW BIRTH WEIGHT; ONTOGENY; PERINATAL ASPHYXIA; PHENOTYPE; PHENOTYPIC VARIATION; PLACENTA CIRCULATION; PREMATURITY; PRESCRIPTION; PRIORITY JOURNAL; REGIONAL PERFUSION;

EID: 84884159539     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2012.03.035     Document Type: Article

References (39)

1. Allegaert, K., Cossey, V., Langhendries, J.P., Naulaers, G., Vanhole, C., Devlieger, H., Van Overmeire, B., 2004. Effects of co-administration of ibuprofen-lysine on the pharmacokinetics of amikacin in preterm infants during the first days of life. Biol. Neonate 86, 207-211. (Pubitemid 39370289)
2. Allegaert, K., Anderson, B.J., van den Anker, J.N., Vanhaesebrouck, S., de Zegher, F., 2007a. Renal drug clearance in preterm neonates: relation to prenatal growth. Ther. Drug Monit. 29, 284-291. (Pubitemid 47262257)
3. Allegaert, K., Peeters, M.Y., Verbesselt, R., Tibboel, D., Naulaers, G., de Hoon, J.N., Knibbe, C.A., 2007b. Inter-individual variability in propofol pharmacokinetics in preterm and term neonates. Br. J. Anaesth. 99, 864-870. (Pubitemid 351773375)
4. Allegaert, K., Verbesselt, R., Naulaers, G., van den Anker, J.N., Rayyan, M., Debeer, A., de Hoon, J., 2008. Developmental pharmacology: neonates are not just small adults. Acta Clin. Belg. 63, 16-24. (Pubitemid 351311069)
5. Allegaert, K., Rochette, A., Veyckemans, F., 2011a. Developmental pharmacology of tramadol during infancy: ontogeny, pharmacogenetics and elimination clearance. Paediatr. Anaesth. 21, 266-273.
6. Allegaert, K., Palmer, G.M., Anderson, B.J., 2011b. The pharmacokinetics of intravenous paracetamol in neonates: size matters most. Arch. Dis. Child. 96, 575-580.
7. Allegaert, K., Smits, A., van den Anker, J.N., 2012. Physiologically based pharmacokinetic modeling in pediatric drug development: a clinician's request for a more integrated approach. J. Biomed. Biotechnol. 2012, 103763.
8. Anderson, B.J., Holford, N.H., 2009. Mechanistic basis of using body size and maturation to predict clearance in humans. Drug Metab. Pharmacokinet. 24, 25-36.
9. Anderson, B.J., Holford, N.H., 2011. Tips and traps analyzing pediatric PK data. Paediatr. Anaesth. 21, 222-237.
10. Bellanti, F., Della Pasqua, O., 2011. Modelling and simulation as research tools in paediatric drug development. Eur. J. Clin. Pharmacol. 67 (Suppl. 1), S75-S86.
11. Bueva, A., Guignard, J.P., 1994. Renal function in preterm neonates. Pediatr. Res. 36, 572-577. (Pubitemid 24331359)
12. Chen, H.L., Liu, Y.L., Chen, H.L., Wu, S.H., Ni, Y.H., Ho, M.C., Lai, H.S., Hsu, W.M., Hsu, H.Y., Tseng, H.C., Jeng, Y.M., Chang, M.H., 2008. Expression of hepatocyte transporters and nuclear receptors in children with early and late-stage biliary atresia. Pediatr. Res. 63, 667-673.
13. Cuzzolin, L., Fanos, V., Pinna, B., di Marzio, M., Perin, M., Tramontozzi, P., Tonetto, P., Cataldi, L., 2006. Postnatal renal function in preterm newborns: a role of diseases, drugs and therapeutic interventions. Pediatr. Nephrol. 21, 931-938. (Pubitemid 43885090)
14. de Cock, R.F., Piana, C., Krekels, E.H., Danhof, M., Allegaert, K., Knibbe, C.A., 2011. The role of population PK-PD modelling in paediatric clinical research. Eur. J. Clin. Pharmacol. 67 (Suppl. 1), 5-16.
15. De Gregori, S., De Gregori, M., Ranzani, G.N., Borghesi, A., Regazzi, A., Stronati, M., 2009. Drug transporters and renal drug disposition in the newborn. J. Matern. Fetal Neonatal Med. 22 (Suppl. 3), S31-S37.
16. De Wildt, S.N., Knibbe, C.A., 2009. Knowledge of developmental pharmacology and modeling approaches should be used to avoid useless trials in children. Eur. J. Clin. Pharmacol. 65, 849-850.
17. FAO. Human Energy Requirements. www.fao.org/docrep/007/y5686e/y5686e03. html (accessed 02.12.11).
18. George, I., Mekahli, D., Rayyan, M., Levtchenko, E., Allegaert, K., 2011. Postnatal trends in creatinemia and its covariates in extremely low birth weight (ELBW) neonates. Pediatr. Nephrol. 26, 1843-1849.
19. Hagos, Y., Wolff, N.A., 2010. Assessment of the role of renal organic anion transporters in drug-induced nephrotoxicity. Toxins (Basel) 2, 2055-2082.
20. Hines, R.N., McCarver, D.G., 2002. The ontogeny of human drug-metabolizing enzymes: phase I oxidative enzymes. J. Pharmacol. Exp. Ther. 300, 355-360. (Pubitemid 34106223)
21. Ho, R.H., Kim, R.B., 2005. Transporters and drug therapy: implications for drug disposition and disease. Clin. Pharmacol. Ther. 78, 260-277. (Pubitemid 41254111)
22. International Transporter Consortium, Giacomini, K.M., Huang, S.M., Tweedie, D.J., Benet, L.Z., Brouwer, K.L., Chu, X., Dahlin, A., Evers, R., Fischer, V., Hillgren, K.M., Hoffmaster, K.A., Ishikawa, T., Keppler, D., Kim, R.B., Lee, C.A., Niemi, M., Polli, J.W., Sugiyama, Y., Swaan, P.W., Ware, J.A., Wright, S.H., Yee, S.W., Zamek-Gliszczynski, M.J., Zhang, L., 2010. Membrane transporters in drug development. Nat. Rev. Drug Discov. 9, 215-236.
23. Johnson, T.N., Rostami-Hodjegan, A., 2011. Resurgence in the use of physiologically based pharmacokinetic models in pediatric clinical pharmacology: parallel shift in incorporating the knowledge of biological elements and increased applicability to drug development and clinical practice. Paediatr. Anaesth. 21, 291-301.
24. Kearns, G.L., Abdel-Rahman, S.M., Alander, S.W., Blowey, D.L., Leeder, J.S., Kaufman, R.E., 2003. Developmental pharmacology: drug disposition, action, and therapy in infants and children. N. Engl. J. Med. 349, 1157-1167. (Pubitemid 37122329)
25. Khalil, F., Läer, S., 2011. Physiologically based pharmacokinetic modeling: methodology, applications, and limitations with a focus on its role in pediatric drug development. J. Biomed. Biotechnol 2011, 907461.
26. Knibbe, C.A.J., Danhof, M., 2011. Individualized dosing regimens in children based on population PKPD modelling: are we ready for it? Int. J. Pharmacol. 415, 9-14.
27. Krumbiegel, P., Domke, S., Mörseburg, B., Boehm, G., Braun, W., 1997. Maturation of hepatosomal mono-oxygenation and glucuronidation activities in pre- and full-term infants as studied using the [15N]-methacetin urine test. Acta Paediatr. 86, 1236-1240. (Pubitemid 27509439)
28. Kuppens, M., George, I., Lewi, L., Levtchenko, E., Allegaert, K., 2011. Creatinaemia at birth is equal to maternal creatinaemia at delivery: does this paradigm still hold? J. Matern. Fetal Neonatal Med. (online available, PMID: 21867404).
29. Laer, S., Barrett, J.S., Meibohm, B., 2009. The in silico child: using simulation to guide pediatric drug development and manage pediatric pharmacotherapy. J. Clin. Pharmacol. 49, 889-904.
30. Leeder, J.S., Kearns, G.L., Spielberg, S.P., van den Anker, J., 2010. Understanding the relative roles of pharmacogenetics and ontogeny in pediatric drug development and regulatory science. J. Clin. Pharmacol. 50, 1377-1387.
31. Ligi, I., Boubred, F., Grandvuillemin, I., Simeoni, U., 2011. Clinical research in newborn infants: difficulties and specificity. Eur. J. Clin. Pharmacol. 67 (Suppl. 1), S29-S32.
32. McCarver, D.G., Hines, R.N., 2002. The ontogeny of human drug-metabolizing enzymes: phase II conjugation enzymes and regulatory mechanisms. J. Pharmacol. Exp. Ther. 300, 361-366. (Pubitemid 34106224)
33. Sweeney, D.E., Vallon, V., Rieg, T., Wu, W., Gallegos, T.F., Nigam, S.K., 2011. Functional maturation of drug transporters in the developing, neonatal and postnatal kidney. Mol. Pharmacol. 80, 147-154.
34. Van den Anker, J.N., Allegaert, K., 2012. Clinical pharmacology in neonates and young infants: the benefit of a population-tailored approach. Expert Rev. Clin. Pharmacol. 5, 5-8.
35. Vieux, R., Hascoet, J.M., Merdariu, D., Fresson, J., Guillemin, F., 2010. Glomerular filtration rate reference values in very preterm infants. Pediatrics 125, e1186-e1892.
36. Vieux, R., Fresson, J., Guillemin, F., Hascoet, J.M., 2011. Perinatal drug exposure and renal function in very preterm infants. Arch. Dis. Child. Fetal Neonatal Ed. 96, F290-F295.
37. Puddu, M., Fanos, V., Podda, F., Zaffanello, M., 2009. The kidney from prenatal to adult life: perinatal programming and reduction of number of nephrons during development. Am. J. Nephrol. 30, 162-170.
38. Yanni, S.B., Augustijns, P.F., Benjamin Jr., D.K., Brouwer, K.L., Thakker, D.R., Annaert, P.P., 2010. In vitro investigation of the hepatobiliary disposition mechanisms of the antifugal agent micafungin in humans and rats. Drug Metab. Dispos. 38, 1848-1856.
39. Yanni, S.B., Smith, P.B., Benjamin Jr., D.K., Augustijns, P.F., Thakker, D.R., Annaert, P.P., 2011. Higher clearance of micafungin in neonates compared with adults: role of age-dependent micafungin serum binding. Biopharm. Drug Dispos. 32, 222-232.